Medicine

Stuart Arbuckle, Vertex’s chief operating officer and one of the company’s longest-tenured leaders, will retire from his role in July. He will be replaced by Charlie Wagner, who will become…

Dive Brief: The Food and Drug Administration on Friday approved a new combination antibiotic developed by AbbVie and Pfizer for tough-to-treat bacterial infections. The drug, named Emblaveo, is cleared for…

Antibody-drug conjugates (ADCs) have emerged as one of the most promising advancements in precision oncology, combining targeted delivery with the potency of traditional chemotherapies. Over the last decade, ADCs have…

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Pfizer on Wednesday named a longtime Novartis executive the leader of an…

Sales of Cobenfy, a new mind-stabilizing medicine, totaled $10 million in the final months of last year, results that fell in line with analyst expectations. Bristol Myers Squibb, which acquired…

Dive Brief: Eli Lilly’s profit doubled in the fourth quarter as the Indianapolis-based drugmaker raked in revenue from diabetes and obesity drugs. Net income rose to $4.4 billion, or $4.88…

Dive Brief: Alumis and Acelyrin are merging, the biotechnology companies said Thursday afternoon, in an all-stock deal that leaves the combined company with a bigger cash balance and three drugs…

Today, a brief rundown of news involving Mitsubishi Tanabe Pharma and Bausch + Lomb, as well as updates from Roche, Viracta Therapeutics and X4 Pharmaceuticals that you might have missed.…

Sionna Therapeutics on Thursday raised $191 million in an initial public offering that will fund its plan to challenge Vertex Pharmaceuticals’ dominant cystic fibrosis franchise. The company sold nearly 10.6…

Dive Brief: Bristol Myers Squibb is expanding its plan to cut costs, announcing alongside quarterly earnings on Thursday that it will slash an additional $2 billion in annual expenses by…

Dive Brief: Novo Nordisk is planning a new Phase 3 trial of its next-generation obesity drug CagriSema that will test different doses and longer duration of treatment, the company said…

Dive Brief: Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly in the last three months of 2024, compared the same period one year before. In…

Dive Brief: Omega Therapeutics, a genetic medicines maker originally backed by Flagship Pioneering, plans to soon file for Chapter 11 bankruptcy as it enters a restructuring agreement with Flagship’s “Pioneering…

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Robert F. Kennedy Jr. made Senator Bill Cassidy a raft of promises…

Dive Brief: Adding Pfizer’s cancer drug Braftovi to standard treatments helped people with a form of colorectal cancer live longer without their disease worsening than those who got the typical…

In a little more than a week’s time, a drug developed by a small psychedelics company was able to significantly curb hard-to-treat depression in a mid-stage clinical trial. That’s according…

The role of China in the pharma market is changing. Until recently Chinese firms were seen by most Western players as a threat, or at the very least, a challenging…

Dive Brief: 23andMe said Tuesday it is exploring “strategic alternatives,” which could include the sale of the company, a business combination or restructuring. The genetic testing company ended 2024 with…

Takeda CEO Christophe Weber plans to retire next year after a decade steering the Japanese drugmaker, a tenure in which he led Takeda through one of the largest pharmaceutical mergers…

Robert F. Kennedy Jr., President Donald Trump’s health secretary nominee, showed limited knowledge about Medicare during his second confirmation hearing on Thursday. It was the second time in two days…

Today, a brief rundown of news involving Novartis and AbbVie, as well as updates from Biogen, Merck & Co. and Sanofi that you may have missed. Novartis on Friday reported…

For the last quarter century, one of the world’s most capable drug developers toiled to make a new, non-addictive kind of painkiller. The journey was fittingly excruciating. Pain, as Vertex…

Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings…

The movement to steer pain treatment away from opioids notched a major victory Thursday, as the Food and Drug Administration approved a new, highly anticipated drug from Vertex Pharmaceuticals. The…

Robert F. Kennedy Jr. on Wednesday told U.S. lawmakers that, if confirmed as the nation’s health secretary, he would support policies from President Donald Trump that would restrict abortion. As…

The Trump administration plans to proceed with negotiating Medicare prices for the next 15 drugs selected under the Inflation Reduction Act, but will seek input to “improve” the program, the…

Dive Brief: A radiopharmaceutical medicine developed by Germany’s ITM outperformed everolimus, an older chemotherapy, in a late-stage study of people with a rare type of neuroendocrine tumor, the biotechnology company…

Multiple lawmakers in Congress reported Tuesday that states were shut out of Medicaid payment portals after the Trump administration enacted a freeze on all federal financial assistance — despite a…

Versant Ventures has made its fourth investment in an obesity startup in eight months, co-leading a $65 million Series A round in Helicore Biopharma, a developer of an antibody drug…

Dive Brief: Sage Therapeutics’ board of directors has turned back partner Biogen’s opportunitistic attempt at a takeover, unanimously rejecting a $469 million offer from Biogen it said “significantly undervalues” the…

Cell & gene therapy stands at the forefront of modern medicine, promising transformative treatments for previously intractable diseases. But, as the field continues to advance, a growing body of evidence…

Artificial intelligence was a topic of focus for the medical device industry in 2024.  Companies including GE Healthcare, Medtronic and Dexcom touted new AI features, and others like Stryker and…

Today, a brief rundown of news involving Merck & Co. and AstraZeneca, as well as updates from AbbVie, Stealth BioTherapeutics and Vigil Neuroscience that you may have missed. A regimen…

As the first major drug industry conference each year, the J.P. Morgan Healthcare Conference is regularly described as a barometer of expectations for the year ahead. This year, JPM delivered…

Dive Brief: An experimental obesity drug from Novo Nordisk helped people lose an average of up to 22% of their body weight over 36 weeks in an early-stage trial, results…

Sara Brenner, a Food and Drug Administration official within the agency’s medical device division, has been named the FDA’s acting commissioner, according to an update made to a webpage listing…

Dive Brief: Ascentage Pharma, a cancer drug developer based in Suzhou, China, on Thursday raised just over $126 million in the first U.S. initial public offering by a biotechnology company…

Prominent vaccine skeptic Robert F. Kennedy Jr. will testify before the Senate Finance Committee on Jan. 29 as he attempts to calm concerns from Democrats and Republicans about his nomination…

Dive Brief: Johnson & Johnson on Wednesday reported modestly higher-than-expected earnings for the fourth quarter, while cautioning that unfavorable currency exchange rates would temper sales growth this year. Adjusted earnings…

Johnson & Johnson expects changes in Medicare’s prescription drug benefit will negatively impact its sales by about $2 billion this year, a modest headwind for a pharmaceuticals division the company…

Moderna will receive some $590 million from the U.S. government to develop messenger RNA vaccines for influenza strains, such as H5N1, that are seen as potential pandemic risks. Announced Friday…

Dive Brief: The Food and Drug Administration on Friday approved AstraZeneca and Daiichi Sankyo’s Datroway for use in people with a common type of breast cancer that has advanced despite…

Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy areas including cancer, diabetes and – inevitably – obesity. Four…

Dive Brief: The Food and Drug Administration needs stricter standards for the accelerated approval process to ensure patients and the healthcare system don’t waste money on ineffective treatments, according to…

SAN FRANCISCO — With the close of J.P. Morgan Healthcare Conference, attention turns to next week’s inauguration of President-elect Donald Trump, and what his administration might mean for the Food…

Dive Brief: Eli Lilly won Food and Drug Administration approval to sell its Omvoh medicine for adults with Crohn’s disease, adding to the potential market for a drug first approved…

Semaglutide, the popular drug sold by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss, is among a group of widely used medicines selected by the U.S. government…

Today, a brief rundown of news involving Novo Nordisk and AstraZeneca, as well as updates from Amgen, Atara Biotherapeutics and Boehringer Ingelheim that you may have missed. A high-dose form…

Medicare’s next drug price negotiations will treat Novo Nordisk’s semaglutide as a single product, regardless of whether the metabolic disease medicine is used to treat diabetes or heart risk, and…

Roche has a big problem. With competition threatening some of its older and most lucrative biologic drugs, the Swiss pharmaceutical giant expects that, in three years time, sales from these…

Soon after starting a new biotechnology company, David Li realized he needed to rethink his strategy.  Li had been conducting the competitive research biotech entrepreneurs typically undertake before soliciting investment.…

This week, the J.P. Morgan Healthcare Conference has brought a torrent of updates from drugmakers large and small. We’re highlighting a few here, but for the rest check out our…

On Tuesday morning, Biogen hosted an event for Wall Street analysts to better understand the company. One of the key topics discussed, according to Brian Abrahams of RBC Capital Markets,…

For any hopes the dealmaking that started the J.P. Morgan Healthcare Conference would give the overall biotechnology sector a running start to 2025, Eli Lilly deflated them Tuesday.  The company,…

Dive Brief: Eli Lilly on Tuesday said the company’s revenue in 2024 totaled about $45 billion, a 32% jump on 2023’s total but less than what it had estimated in…

As 2025 begins, emerging biotechnology firms can be sorted into two groups: haves and have-nots. Venture funding rose last year, but a good portion of that money was concentrated into…

Late last week, Biogen made an unsolicited offer to buy one of its partners, brain drug developer Sage Therapeutics. The two biotechnology companies have worked together over the past four…

In 2023, the biosimilar drug market in the Asia-Pacific (APAC) region was valued at $1.65 billion. Accelerating patient recruitment, managing costs and expanding market access are essential to meet the…

Dive Brief: An experimental menopause drug from Bayer succeeded in a late-stage trial in women taking drugs to treat or prevent breast cancer, the company said Thursday. Bayer said the…

Dive Brief: Ouro Medicines, a new biotechnology startup, launched Friday with $120 million in funding to develop antibody drugs for chronic inflammatory conditions. Ouro plans to use so-called T cell…

Dive Brief: Intellia Therapeutics will stop work on one of its principal drug research programs and lay off more than one-quarter of its staff in a restructuring meant to prioritize…

Patrizia Cavazzoni, an influential Food and Drug Administration official who oversees much of the agency’s drug review work, will leave her role next week, according to an email sent to…

Today, a brief rundown of news involving Pfizer, AbbVie and Royalty Pharma, as well as updates from Biogen and Alkeus Pharmaceuticals that you may have missed. Pfizer on Friday said…

Typically, the election of a Republican to the White House is welcome news for the biotechnology and pharmaceutical sectors. The incoming administration is a more uncertain prospect, however. President-elect Donald…

IGM Biosciences will scrap its top two drugs and lay off nearly three-quarters of its workforce after reporting study results that fell short of the company’s expectations. In an announcement…

Maze Therapeutics on Tuesday filed plans for an initial public offering that could become the biotechnology sector’s first of the year, depending on how quickly the deal comes together. If…

GSK’s and Pfizer’s vaccines for respiratory syncytial virus must carry labels warning of a possible increased risk of a rare neurological disorder, the Food and Drug Administration said Tuesday. The…

Dive Brief: Privately-held biotechnology startup Metsera said Tuesday a long-acting GLP-1 shot it’s developing helped people who are overweight or have obesity lose more weight than placebo recipients in a…

Dive Brief: Vertex Pharmaceuticals will work together with Orna Therapeutics over the next three years to develop technology that would help enable “in vivo” gene therapies for sickle cell disease…

About four years ago, Sheldon Koenig was thinking about retiring. After spending decades in leadership roles at different pharmaceutical companies, he’d led a successful career focused largely on cardiovascular therapeutics.…

Dive Brief: Orbis Medicines, a European biotechnology startup, has raised 90 million euros, or about $93 million, in a Series A round announced Monday that will fund development of oral…

Incretin drugs have been so successful in clinical testing they’re akin to a pharmaceutical Swiss Army knife. Already, medicines from Novo Nordisk and Eli Lilly approved to treat obesity and…

The Food and Drug Administration ended 2024 with a quartet of notable drug approvals, including three of new medicines that Vertex Pharmaceuticals, Novo Nordisk and Bristol Myers Squibb developed for…

Neumora Therapeutics, a well-funded biotechnology company, lost more than 80% of its value Thursday because its most advanced drug failed a major test. After seeing positive signs in a smaller…

Happy New Year! We hope you had a restful holiday; If you took a break from keeping up with biotech news, we’ve got you covered with a brief rundown of…

The Food and Drug Administration on Thursday reaffirmed its assessment that Mounjaro and Zepbound, popular drugs for diabetes and obesity, are no longer in shortage, The agency’s decision will largely…

Swiss pharmaceutical company Novartis plans to close MorphoSys sites in the U.S. and Germany in a “strategic decision” that will affect 330 jobs. The move, which was first reported by…

Vertex Pharmaceuticals lost more than $15 billion in value Thursday as new data on its closely watched pain drug disappointed Wall Street. The medication is meant to be a non-addictive…

Dive Brief: Regeneron Pharmaceuticals intends to advance two blood-thinning drugs into Phase 3 testing next year after mid-stage study results showed they matched or surpassed marketed medicines at preventing blood…

A new type of obesity drug being developed by Novo Nordisk has fallen short of expectations set by the company in a closely watched Phase 3 trial, causing shares to…

Today, a brief rundown of news involving Ionis Pharmaceuticals and the Food and Drug Administration, as well as updates from Zealand Pharma, Sangamo Biosciences and Novartis that you may have…

An experimental drug for Parkinson’s disease that Roche has been developing for more than a decade just flunked another key clinical trial. But in spite of those failures, the drug’s…

KdT Ventures is launching a new biotechnology startup based on a drug it’s licensing from NGM Biopharmaceuticals, the companies announced Thursday. The deal hands the Austin-based venture firm’s currently unnamed…

David Epstein was ready to retire when an opportunity came along he couldn’t pass up. Epstein had just sold Seagen, a large cancer drugmaker, to Pfizer for $43 billion and…

Dive Brief: Merck & Co. has made its first big move in obesity treatment, announcing Wednesday it is paying Hansoh Pharma $112 million for rights outside China to a preclinical…

Dive Brief: Doctors could have a new treatment option for protecting newborn infants from respiratory syncytial virus if the Food and Drug Administration approves Merck & Co.’s drug clesrovimab by…

Namandjé Bumpus, the Food and Drug Administration’s second-in-command, will depart the regulator at the end of the year, according to an email FDA Commissioner Robert Califf sent to agency staff…

Jazz Pharmaceuticals on Monday said it will begin searching for a successor to CEO Bruce Cozadd, who plans to retire from the company he helped start more than two decades…

Dive Brief: Edgewise Therapeutics plans to meet with regulators in the U.S. and Europe to discuss how much clinical trial evidence it needs to seek expedited approval of its experimental…

Dive Brief: Keros Therapeutics shares plummeted Thursday after the company said researchers conducting a Phase 2 study have stopped giving patients the two highest doses of its lead experimental drug…

The Food and Drug Administration has identified additional safety concerns associated with use of a drug used to treat a rare liver condition in the latest sign of trouble for…

Dive Brief: AbbVie will pay $200 million to acquire privately held Nimble Therapeutics and its pipeline of oral peptide drugs for immune diseases like psoriasis and inflammatory bowel disease, the…

Today, a brief rundown of news involving Gilead and Padlock Therapeutics, as well as updates from Boundless Bio, Lonza and Bausch + Lomb that you may have missed. Investors of Padlock…

A panel of experts convened by the Food and Drug Administration called for more data to be collected on the safety of vaccines for respiratory syncytial virus in infants, indicating…

In a rare move, the U.S. agency behind Medicare is warning insurers who provide Medicare Advantage plans that they can’t automatically deny coverage of Qalsody, a Biogen drug approved to…

Dive Brief: Editas Medicine will lay off 180 employees, or about two-thirds of its workforce, over the next six months as part of a broader pivot to focus its drug…

Research into women’s health has long gone underfunded in the U.S. But there’s some optimism that might be changing, attendees to the first conference hosted by the White House on…

Dive Brief: Shares of Q32 Bio lost two-thirds of their value Wednesday after the company reported disappointing study results for an experimental medicine in two indications. The drug, bempikibart, is…

An experimental breast cancer drug developed by Eli Lilly met its main goal in a Phase 3 study, helping people with a form of HER2-negative, ER-positive disease stay alive and…

Shares of UniQure doubled Tuesday morning after the Netherlands-based biotechnology company trumpeted that its experimental treatment for Huntington’s disease could be eligible for a speedy kind of approval. Known as…

The American Society of Hematology’s annual meeting continued Monday with important presentations and discussions on the latest blood disease research, several of which we’ve summarized here. Sequencing BTK inhibitors in…

One year on from the landmark U.S. approval of two powerfully effective gene therapies for sickle cell disease, the treatments have been barely used, a sluggish start that reflects the…

This weekend, thousands of researchers and physicians descended on San Diego for the American Society of Hematology’s annual meeting. While BioPharma Dive wasn’t on site this year, we’ve summarized a…

Today, a brief rundown of news involving Novavax and Novo Nordisk, as well as updates from Relay Therapeutics, Takeda and Tubulis that you may have missed. Novavax has agreed to…

Inside every human cell are thousands of snippets of genetic code that serve as the directions for creating proteins. And over the past four years, a small biotechnology company has…

Today, a brief rundown of news involving Daiichi Sankyo, Agenus and Amgen, as well as updates from the U.S. PTO, Bluebird bio and Merus that you may have missed. AstraZeneca…

Dive Brief: BioAge Labs said it is terminating a mid-stage study of its obesity drug candidate azelaprag in combination with Eli Lilly’s tirzepatide due to safety concerns, causing its share…

Eli Lilly will spend $3 billion to expand a manufacturing facility in Wisconsin it bought in April, adding new capabilities to produce injectable medicines like its fast-selling weight loss and…

Robert F. Kennedy Jr., chosen by President-elect Donald Trump to be the next health secretary, has made it his mission to dissipate what he describes as a “smothering cloud of…

Biotechnology startup Nuvig Therapeutics is the latest emerging immune drug developer to attract investors’ attention, announcing Thursday a $161 million Series B round to bring its lead candidate into mid-stage…

Dive Brief: Atlas Venture said Thursday that it’s raised $450 million for its 14th fund, through which the firm will continue to seed and grow new biotechnology companies.   Partner Bruce…

Dive Brief: Atea Pharmaceuticals said Wednesday that its experimental combination regimen to treat the hepatitis C virus succeeded in a Phase 2 trial, clearing the way for Phase 3 research…

Dewpoint Therapeutics, a young biotechnology company, could receive nearly half a billion dollars if all goes to plan in a new partnership focused on its experimental medicine for ALS. Through…

Coherus BioSciences has reached a deal to sell another one of its biosimilars as part of a plan to make cancer immunotherapies its focus going forward. The company on Tuesday…

Shares of Janux Therapeutics surged to record highs following the release of study results for a drug that, if ultimately successful in testing, would represent a new type of therapy…

The American Diabetes Association, a high-profile advocacy group, is warning against widespread use of compounded versions of popular weight loss and diabetes drugs like Wegovy and Zepbound. The group on…

Today, a brief rundown of news involving Novocure and Merus, as well as updates from Cytokinetics, Fate Therapeutics and Bluebird bio that you may have missed. Novocure said its electrical…

Brain drug developer Alector is laying off staff after one of its most advanced experimental medicines failed to show enough promise as a treatment for Alzheimer’s disease. For the past…

Swiss pharmaceutical giant Roche is spending around $1 billion to acquire a San Diego-based biotechnology company that’s trying to treat certain cancers and rare diseases with a slate of cell…

Roche’s long-running bet on a new kind of cancer immunotherapy has, after years of shrinking optimism and second-guessing by analysts on Wall Street, come up empty — at least for…

Today, a brief rundown of news involving Kronos Bio, Idorsia and PTC Therapeutics, as well as updates from Alnylam Pharmaceuticals and Soleno Therapeutics that you may have missed. Kronos Bio…

Dive Brief: Sarepta Therapeutics has turned to dealmaking to restock a drug pipeline analysts worried was growing thin, announcing Tuesday a deal with Arrowhead Pharmaceuticals that will give it four…

For drug companies, predicting how much money a product will make is a risky endeavor. If the estimate ends up being far off, then investors may question how well a…

Dive Brief: Amgen on Tuesday said its weight loss drug MariTide helped people with obesity lose up to 20% of their body weight over one year in a Phase 2…

The Biden administration on Tuesday proposed a rule that would allow Medicare and Medicaid to cover weight loss drugs for patients with obesity. The rule — if kept by the…

Dive Brief: An experimental, muscle-preserving drug from Biohaven fell short of its goal in a Phase 3 study of people with spinal muscular atrophy, but showed enough promise in its…

Dive Brief: Adding Merck & Co.’s new cardiovascular drug Winrevair to background therapy helped people with severe lung hypertension stay alive and avoid invasive medical care longer than those who…

Howard Chang, a top biotechnology researcher and longtime professor at Stanford University, will join Amgen as chief scientific officer on Dec. 16, the company said Wednesday. Chang will also assume…

Retail pharmacy giants have been straining under the intense headwinds hitting the industry this year — and Walgreens’ most recent earnings provided another case in point. The company said in…

Dive Brief: Lexicon Pharmaceuticals will lay off 60% of its workforce and eliminate its commercial organization in a restructuring meant to save $100 million in operating costs next year. The…

The Food and Drug Administration has approved a new medicine for a deadly genetic heart condition, boosting its developer, BridgeBio Pharma, and teeing up a battle for control of a…

President-elect Donald Trump on Friday named Johns Hopkins University surgeon Marty Makary to lead the Food and Drug Administration, choosing a prolific medical researcher who bucked consensus on the necessity…

Today, a brief rundown of news involving Halozyme and Neurogene, as well as updates from Argenx and Kura Oncology that you may have missed. Halozyme Therapeutics on Friday said it…

Through a new deal, Novartis has added a handful of experimental gene therapies to its neuroscience research pipeline. Novartis is betting the gene therapy technologies developed by Kate Therapeutics, a…

Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning…

Pfizer on Wednesday said it will promote Chris Boshoff to chief scientific officer and president of research and development as the giant drugmaker struggles to win back the faith of…

Sage Therapeutics is shelving one of its most important experimental drugs, after a last-ditch effort to prove it can be useful in nerve-destroying disorders ended in failure. On Wednesday, Sage…

Today, a brief rundown of news involving Astellas and Cytokinetics, as well as updates from Cybin, Neurogene and Novartis that you may have missed. The Food and Drug Administration rejected…

Dive Brief: An experimental under-the-skin injection of Merck & Co.’s cancer immunotherapy Keytruda showed similar characteristics as the current intravenous formulation in a Phase 3 clinical trial, the company said…

Dive Brief: Massachusetts-based Syndax Pharmaceuticals won Food and Drug Administration approval Friday for a new kind of drug to treat an aggressive form of leukemia in adults and some children. The…

Dive Brief: Regenxbio has aligned with the Food and Drug Administration on an abbreviated approval path for an experimental gene therapy the company has been developing for Duchenne muscular dystrophy.…

Merck & Co. has bought into the kind of drug that has emerged as a top threat to its dominant cancer immunotherapy Keytruda. The company said Thursday it agreed to…

In an unusual reversal, key drug regulators in Europe are now saying Leqembi, a high-profile medicine for Alzheimer’s disease, should be approved there, though only for patients less likely to…

Today, a brief rundown of news involving Evotec, Bluebird bio and the company formerly known as BeiGene, as well as updates from Leerink Partners and Abeona Therapeutics that you may…

Failure is more common than success for young biotechnology companies attempting to get a new drug onto the market. Drug development is rife with pitfalls, from disappointing clinical trial results…

Trace Neuroscience, a freshly launched startup, is developing a type of genetic medicine it believes could help most, if not all, people with ALS. It’s a bold idea, considering nearly…

Market downturns take a toll. For many young biotechnology companies, the past few years have been a lesson in survival, as the evaporation of the sector's pandemic-era boom brought cutbacks…

President-elect Donald Trump plans to nominate Robert F. Kennedy Jr. to lead the Department of Health and Human Services in a controversial choice that would elevate the prominent vaccine skeptic…

Dive Brief: PTC Therapeutics on Wednesday won Food and Drug Adminitration approval for Kebilidi, the first gene therapy cleared in the U.S. for direct administration to the brain. The treatment…

Dive Brief: Metsera, already a well-funded biotech startup, added another $215 million to its coffers as investors responded to the promise of its obesity drug pipeline. Wellington Management and Venrock…

Today, a brief rundown of news involving Amgen and AstraZeneca, as well as updates from Roche, Novartis, and Centessa Pharmaceuticals that you may have missed. Amgen lost $12 billion in…

Flagship Pioneering startup Vesalius Therapeutics has signed a deal with GSK, the companies announced Tuesday, for the British pharma to use its technology to find medicines for neurodegenerative disorders. Under…

Dive Brief: The Food and Drug Administration on Friday approved a new cell therapy for a type of leukemia. Called Aucatzyl, the CAR-T was developed by U.K.-based Autolus Therapeutics to…

Through a recent, nearly $9 billion acquisition, AbbVie surged to the front of a new wave of antipsychotic drugs that Wall Street expects to become big sellers. But on Monday,…

For sponsors and CROs, reducing time-to-market and improving patient access to innovative treatments remain pressing challenges and top priorities. From regulatory hurdles and logistical complexities to patient recruitment and retention,…

Acadia Pharmaceuticals agreed to sell a priority review voucher to an undisclosed buyer for $150 million, a price tag on the high end for the coveted passes that speed up…

With the U.S. presidential election decided, one name is suddenly circulating in healthcare: Robert F. Kennedy Jr. President-elect Donald Trump has promised Kennedy a large role in his new administration,…

Dive Brief: Athira Pharma, a small drugmaker focused on neuroscience, is looking into the different paths it could take to “maximizing stockholder value,” after the company’s most advanced experimental medicine…

Today, a brief rundown of news from AstraZeneca, Amgen and Jazz Pharmaceuticals, as well as updates from Geron, Gilead Sciences and Avid Bioservices that you may have missed. AstraZeneca and…

Public biotechnology company AlloVir has agreed to merge with the privately held Kalaris Therapeutics, nearly one year after a clinical setback sunk its stock price and its options. Through a…

Dive Brief: Sarepta Therapeutics is giving up on an experimental drug for Duchenne muscular dystrophy as sales rocket for its approved gene therapy for the disease. The decision to discontinue…

Dive Brief: Moderna on Thursday reported third quarter sales of its COVID-19 vaccine that substantially outperformed analyst expectations. The company didn't raise its financial outlook for the year, however, suggesting…

Donald Trump’s victory in the U.S. presidential election Tuesday means change is coming for federal health agencies and the industries they regulate. It’s just not quite clear yet how dramatic…

Dive Brief: Dive Insight: Novo and Lilly are racing to build on their dominant obesity drug businesses. Both are working to broaden use of their therapies, while also working on…

Research into RNA interference, a Nobel Prize-winning technique to mute disease-causing gene mutations, has gained momentum in recent years. Since 2018, six medicines based on the technology have won approval…

Dive Brief: A cancer cell therapy developed by Arcellx and Gilead Sciences helped reduce or eliminate signs of multiple myeloma in 95% of people in advanced stages of disease, the…

Sana Biotechnology will lay off staff and shift its research focus in the latest retrenchment for a company only three years removed from one of the biotechnology sector’s most lucrative…

Neurogene, a gene therapy developer focused on rare neurological diseases, has secured $200 million through a private funding deal that will extend its cash reserves into late 2027. The company…

As the third generation of PCR technology, digital PCR introduced powerful new capabilities to countless research applications. Features such as improved precision and sensitivity, absolute quantification of nucleic acids, and…

Michelle Tarver, the new leader of the Food and Drug Administration’s medical device center, faces significant challenges. Tarver is taking over as director of the Center for Devices and Radiological…

California biotechnology startup Evommune has raised $115 million to advance a pair of medicines it’s developing for chronic immune conditions. The Series C funding announced Thursday will support a trio…

Dive Brief: Compass Pathways said it will lay off 30% of its workforce, narrow its research focus and explore selling its digital technologies after pushing back the timeline for its…

Today, a brief rundown of news from Regeneron Pharmaceuticals and Madrigal Pharmaceuticals, as well as updates from UCB, AbbVie and PTC Therapeutics that you may have missed. Shares of Regeneron…

Novo Nordisk will seek regulatory approval of semaglutide, the key ingredient in its popular weight loss medicine, in a common liver disease following positive results in a Phase 3 trial,…

Dive Brief: Jade Biosciences, a privately held developer of immune disease drugs, will combine with Aerovate Therapeutics in a reverse merger that gives Jade a fast pass to trade on…

Dive Brief: Roche may seek an accelerated U.S. approval of its experimental Alzheimer’s disease drug trontinemab if the therapy continues to show in testing it can significantly lower levels of…

Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand, sending shares in the British pharmaceutical company down 3% in U.S. trading Wednesday. GSK, which had…

All doses of Novo Nordisk's popular GLP-1 medicines Ozempic and Wegovy are available in the U.S. and being regularly shipped to wholesalers, the drugmaker confirmed Wednesday. One dose form or…

Archon Biosciences came about as most startups do, the result of happenstance and good timing. Unlike many, the biotechnology company also had a Nobel Prize winner to help it along.…

Sales of Pfizer’s new vaccine for respiratory syncytial virus were lower in the third quarter than during the same period last year, but the company pointed to signs of growing…

Pfizer, facing down a contentious challenge from an activist investor, reported earnings for the third quarter Tuesday that handily beat Wall Street forecasts and led it to boost revenue guidance…

AbbVie has agreed to acquire a young company with drugmaking technology from Johnson & Johnson and an experimental treatment for Alzheimer’s disease that’s in the first stage of human testing.…

Managing biospecimens is a critical, yet often overlooked, part of ensuring a clinical trial’s success. Biospecimen managers are a resource that provides full lifecycle biospecimen oversight, from collection to sample…

Dive Brief: Intellia Therapeutics on Thursday released detailed Phase 2 results from a study of a gene-editing therapy for hereditary angioedema, drawing mixed reactions from investors and experts. The therapy,…

Dive Brief: Kivu Biosciences, a San Francisco-based biotechnology startup developing targeted drugs for cancer, has raised $92 million in a Series A round, the company said Monday. Kivu will use…

A panel of advisers to the Centers for Disease Control and Prevention on Wednesday recommended lowering the age for routine pneumococcal vaccination from 65 to 50 years of age, boosting…

Today, a brief rundown of news from GSK and Amgen, as well as updates from Roche, AbbVie, and Marinus Pharmaceuticals that you may have missed. Amgen set a list price…

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus,…

Septerna, a developer of medicines that target a ubiquitous family of proteins, on Thursday priced a $288 million initial public offering that again showed investors’ support of biotechnology companies that…

Lyell Immunopharma, a cell therapy developer that has struggled to match its high profile, is acquiring a biotechnology startup and streamlining research in a bid to focus on a slate…

In the world of drug discovery, a lot can change in 20 years. Over the past two decades, biotechnology companies brought to market a wave of biologic medicines that changed…

Alto Neuroscience, a young biotechnology company developing medicines for the brain, lost much of its value Wednesday as negative results from a clinical trial raised doubts about the future of…

Starboard Value, the activist investor agitating for change at Pfizer, called on the pharmaceutical giant’s board of directors to hold the company’s executives responsible for what it described as a yearslong…

The Food and Drug Administration on Tuesday named Michelle Tarver as the permanent director of the agency’s device center. Tarver was appointed as acting director of the Center for Devices…

Thorsten Stafforst remembers being told to stop wasting his time. It was early last decade and scientists across the world were buzzing over a new tool, called CRISPR, that could…

Dive Brief: French pharmaceutical company Sanofi is proceeding with plans to sell U.S.-based private equity firm Clayton Dubilier & Rice a controlling stake in its consumer health busines Opella, which…

The biopharmaceutical industry has been a hotbed of innovation in recent years, with an increasing number of novel recombinant protein therapeutics receiving the U.S. Food and Drug Administration's (FDA) green…

Dive Brief: Sanofi will invest 300 million euros, or about $325 million, for a roughly 16% stake in a new joint venture set up to develop radiopharmaceutical drugs for rare…

Dive Brief: CVS Health on Thursday replaced CEO Karen Lynch as the healthcare and pharmacy giant’s financial challenges mount. CVS’ new chief executive is David Joyner, a company veteran who most…